a leading precision medicine company utilizing artificial intelligence (AI) to enhance cancer treatment, has announced its expansion into human oncology. Building on its successful work in veterinary oncology, ImpriMed will now offer precision medicine services for human blood cancers, including newly diagnosed multiple myeloma and acute myeloid leukemia. Additionally, the company will present groundbreaking research on treatment outcomes for naïve non-Hodgkin lymphoma at the upcoming EHA-SfPM Precision Medicine Meeting in Copenhagen, Denmark, from September 25-27, 2024.
ImpriMed Human Oncology Services
Precision medicine aims to provide personalized treatments based on a patient’s unique genetic and biological profile, significantly improving treatment outcomes. ImpriMed’s human oncology services will address complex blood cancers through a combination of genomic analysis, ex vivo drug sensitivity testing, and AI-driven predictions. Their initial offerings include:
- Newly Diagnosed Multiple Myeloma (NDMM): ImpriMed’s NDMM platform utilizes AI and patient data to predict treatment outcomes and early disease progression without the need for biological samples.
- Acute Myeloid Leukemia (AML): By evaluating drug sensitivity test results for 21 anticancer drugs, ImpriMed’s technology predicts patient responses, helping oncologists tailor treatment plans to improve survival outcomes.
- Non-Hodgkin Lymphoma (NHL): ImpriMed’s innovative ex vivo drug sensitivity tests accurately predict treatment outcomes for NHL, enabling more personalized and effective treatment protocols.
Participation in EHA-SfPM Precision Medicine Meeting
At the upcoming EHA-SfPM meeting, ImpriMed CEO Dr. Sungwon Lim will present the company’s expansion into human oncology with a poster titled “Predicting Treatment-Specific Outcomes for Naïve Non-Hodgkin Lymphoma Using Ex Vivo Drug Sensitivity Analyses.” This study demonstrates the potential of ex vivo testing to predict outcomes and guide therapeutic decisions for NHL patients, potentially improving survival rates.
This presentation marks a significant step forward in ImpriMed’s use of AI and drug sensitivity analysis to predict personalized drug responses in human oncology. Previously, ImpriMed shared its insights on AML treatment at the 2023 American Society of Hematology Annual Conference, showcasing its ongoing contributions to the field.
Expanding Impact in Cancer Care
“The expansion of ImpriMed’s precision medicine services from veterinary to human oncology is a major milestone in our mission to revolutionize cancer treatment,” said Dr. Lim. “Our AI-powered technology empowers oncologists to predict treatment outcomes more accurately, allowing for truly personalized therapies for every patient. We’re excited to extend our contract research organization (CRO) services, helping develop new cancer treatments and improving patient outcomes.”
ImpriMed is also a sponsor of the EHA-SfPM event, which brings together global experts to explore the future of predictive diagnostics and drug development for both blood and solid tumors. As part of its CRO services, ImpriMed will provide pharmaceutical companies access to its advanced live-cell analysis platform, which evaluates the efficacy of novel drug compounds on live cancer cells from patients.
With this expansion, ImpriMed aims to support more personalized cancer therapies and give hope to patients in their cancer journeys.
